Netherlands’ Medicines Evaluations Board has ordered marketing authorization holders of promethazine-containing drugs to add to product packaging a warning about hallucinations as a possible side effect of use.
The regulator said it was acting after the national pharmacovigilance center, Bijwerkingencentrum Lareb, received 11 reports of hallucinations associated with...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?